Respiratory

Hydroxychloroquine has been widely used for treatment of COVID-19, despite the lack of strong evidence supporting its efficacy.

New clinical trial updates on remdesivir as a potential treatment for coronavirus disease 2019 (COVID-19) were announced today.

Regeneron and Sanofi will amend their ongoing trial of sarilumab (Kevzara) to enroll only “critical” hospitalized patients with COVID-19.

The guidelines provide clinical recommendations to providers treating patients with coronavirus disease 2019 (COVID-19).

In 2 prior clinical studies, gimsilumab demonstrated favorable results in treating the novel coronavirus.

In collaboration with Spectrum Solutions and Accurate Diagnostic Labs, RUCDR Infinite Biologics developed the new collection approach, which utilizes saliva as the primary test biomaterial for COVID-19. 

Children with the novel coronavirus disease 2019 (COVID-19) may not develop a fever or cough as often as adults with the virus.

As COVID-19 continues to spread, and the death toll rises, experts aim to better understand the clinical features of the disease and factors for increased mortality.

The study will evaluate ruxolitinib (Jakavi) for the treatment of COVID-19-associated cytokine storm.

Tissue plasminogen activator, which is used to treat blood clots, may help severely ill patients with COVID-19 who are in respiratory failure, according to a new paper.

Due to the increased need for albuterol inhalers in hospitals for COVID-19, shortages have been occurring in some areas of the country and will likely continue to affect supplies.

Relieving symptoms and optimizing therapies for allergic rhinitis

Nintedanib (Ofev, Boehringer Ingelheim Pharmaceuticals) has been approved for the treatment of chronic fibrosing interstitial lung disease with a progressive phenotype.

Solid recommendations can require detective work. 

The FDA is requesting that manufacturers of bacitracin for injection voluntarily withdraw their product. 

Data tracked by wearable fitness sensors may help with real-time surveillance of seasonal respiratory infections, such as influenza.

The 2019 Novel Coronavirus outbreak in Wuhan City, China has caused concern as 2 cases have been recently reported in the United States.

Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.

A new study of a vaccine used against a pneumonia-causing bacteria found that cases of severe pneumonia decreased by 35% among those children who had received the vaccine.

Pharmacists can play an integral role in transitions-of-care for patients with chronic obstructive pulmonary disease (COPD) to prevent hospital readmissions.

Tips to help COPD patients decrease their flare-up risks.

The range of inhaled therapies has expanded dramatically in recent years.

Direct and concise information will dissuade dangerous use.

Fewer tracheobronchial branches may be a genetically-related risk factor.

Regular exercise can be an effective way to delay the onset and acceleration of COPD.